Exploratory Investigation Into Perioperative Treatment Strategies for Potentially Resectable Stage III – N2 Driver Gene–Negative Non–Small Cell Lung Cancer in the Immunotherapy Era
Cancer Medicine · 2026-03 · 15 (3)
DOI: 10.1002/cam4.71696 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 08.03.2026. Verfasst von Jiarui Zhao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, and Shandong Academy of Medical Sciences…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunotherapy, Perioperative Care. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Science and Technology Major Project, Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Background
Comparisons among treatment strategies for potentially resectable Stage III–N2 driver gene–negative non–small cell lung cancer (NSCLC) remain limited. We evaluated three treatment strategies—neoadjuvant chemoimmunotherapy followed by surgery (NCIT+surgery), NCIT followed by chemoradiotherapy (NCIT+CRT), and definitive concurrent chemoradiotherapy followed by immunotherapy (CRT + IT)—to investigate whether CRT could represent a feasible option to surgery.
Methods
Patients with Stage III–N2 NSCLC from two institutions (2019–2024) were retrospectively enrolled. Primary endpoints were progression‐free survival (PFS) and overall survival (OS). Subgroup analyses included metastatic N2 lymph node status, stage, programmed death ligand 1 expression, radiographic response to NCIT, and adjuvant or consolidation immunotherapy after surgery or CRT. Baseline differences were balanced 1:1 by propensity score matching (PSM). Survival was estimated by the Kaplan–Meier method and compared via the log‐rank test.
Results
A total of 363 patients were included: NCIT+Surgery ( n = 176), NCIT+CRT ( n = 55), and CRT + IT ( n = 132). The median follow‐up time was 31.5 months. Before and after PSM, PFS, and OS were longer in NCIT+Surgery than in CRT + IT, whereas no significant difference was observed between NCIT+Surgery and NCIT+CRT. Subgroup analysis showed that survival did not differ significantly between NCIT+Surgery and CRT + IT in patients with multistation or bulky N2 metastasis, whereas CRT + IT was associated with inferior PFS and OS in patients without these features.
Conclusions
Survival did not differ significantly between CRT and surgery after NCIT, nor between CRT + IT and NCIT + Surgery among patients with multistation or bulky N2 disease. Whether CRT can serve as an alternative to surgery in this population requires validation in large‐scale prospective studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
- School of Clinical Medicine, Shandong Second Medical University, Weifang, China.
- Shandong University Cancer Center, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
- Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
ORCID-Profile: Menglin Bai, Guoxin Cai
Förderung
- National Natural Science Foundation of China
- National Science and Technology Major Project
- Natural Science Foundation of Shandong Province
- Shandong Province University "Youth Innovation Team Program"
- Chinese Society of Clinical Oncology
- Collaborative Academic Innovation Project of Shandong Cancer Hospital
Zitieren
APA
Zhao, J., Huang, B., Li, M., Wang, X., Zhu, J., Wang, K., Xu, J., Wang, X., Bai, M., & Cai, G. (2026). Exploratory Investigation Into Perioperative Treatment Strategies for Potentially Resectable Stage III – N2 Driver Gene–Negative Non–Small Cell Lung Cancer in the Immunotherapy Era. Cancer Medicine, 15(3). https://doi.org/10.1002/cam4.71696
Vancouver
Zhao J, Huang B, Li M, Wang X, Zhu J, Wang K, et al. Exploratory Investigation Into Perioperative Treatment Strategies for Potentially Resectable Stage III – N2 Driver Gene–Negative Non–Small Cell Lung Cancer in the Immunotherapy Era. Cancer Medicine. 2026;15(3). doi:10.1002/cam4.71696
BibTeX
@article{Zhao2026,
author = {Zhao, Jiarui and Huang, Baiyang and Li, Min and Wang, Xingpeng and Zhu, Jingyu and Wang, Kaiyue and Xu, Jing and Wang, Xiaohan and Bai, Menglin and Cai, Guoxin},
title = {Exploratory Investigation Into Perioperative Treatment Strategies for Potentially Resectable Stage III – N2 Driver Gene–Negative Non–Small Cell Lung Cancer in the Immunotherapy Era},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {3},
doi = {10.1002/cam4.71696}
}
EUVIMED